AD

Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years

Retrieved on: 
Friday, October 20, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Almirall, Lilly, Eli Lilly and Company, AD, Aes, Eli Lilly, Adherence, Conference, Maintenance, Addiction severity index, Conditional sentence, IGA, Shingles, Abstract, The New England Journal of Medicine, Conjunctivitis, British Journal of Dermatology, Atopic dermatitis, Patient, Pharmaceutical industry, Dermatology, Tree-adjoining grammar, EASI

In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.

Key Points: 
  • In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.
  • The most common side effects of lebrikizumab were conjunctivitis, injection site reactions and shingles (herpes zoster).
  • “Results from ADjoin reinforce the strong efficacy and safety profile of lebrikizumab seen in the other Phase 3 atopic dermatitis trials.
  • Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.

Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

Retrieved on: 
Friday, October 20, 2023
Science, Neurology, Radiology, Biotechnology, Research, Health, Medical Devices, Genetics, AD, Positron emission tomography, Neurodegenerative disease, MD, Party, PET, ADNI, Brain, Diagnosis, Acceleration, Medical imaging

Meilleur Technologies, Inc. today announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4, on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status amyloid plaque in the brain.

Key Points: 
  • Meilleur Technologies, Inc. today announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4, on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status amyloid plaque in the brain.
  • Amyloid plaques are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease (AD).
  • The collaboration is focused on using [F-18]NAV-4694 as an imaging biomarker in ADNI4’s neurodegenerative disease research.
  • The Parties will apply [F-18]NAV-4694 imaging to aid ADNI4’s goal of a better understanding of AD to improve diagnosis and treatment of the devastating disease.

LEO Pharma Presents Adbry® (tralokinumab-ldrm) Data at 2023 Fall Clinical Dermatology Conference

Retrieved on: 
Friday, October 20, 2023
Biotechnology, Pharmaceutical, Health, Janus, Tralokinumab, Patient, Adolescence, AD, Ageing, Catalog, Leo Pharma, Conference, Systematic review, Research, RWE, Meta-analysis, TRACE, Various, Disease, S. aureus, Safety, Atopic dermatitis, LEO, Pharmaceutical industry, Vaccine

LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of new clinical and real-world data around tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of new clinical and real-world data around tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis (AD).
  • The drug is marketed in the U.S. as Adbry® for adult patients (aged 18+ years) with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
  • The findings are being presented across 12 posters at the 2023 Fall Clinical Dermatology Conference taking place in Las Vegas, Nevada, from October 19-22, 2023.1-12
    “We are thrilled to present such a wealth of tralokinumab-ldrm data, which will further develop our understanding of how to meet the needs of patients living with atopic dermatitis,” says Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma.
  • “The breadth and depth of LEO Pharma data being presented at the Fall Clinical Dermatology Conference this year will showcase our leadership in the medical dermatology space and our continued commitment to the whole patient community.

Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis

Retrieved on: 
Thursday, October 19, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, AD, Itch, Therapy, Skin, MAD, Inflammation, SAD, Pharmacokinetics, Numabe Station, Safety, Atopic dermatitis, European, Patient, SC, Pharmaceutical industry, Vaccine

Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the first patient has been dosed in the multiple ascending dose (MAD) study of the Phase 1a/b clinical trial of NM26, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the first patient has been dosed in the multiple ascending dose (MAD) study of the Phase 1a/b clinical trial of NM26, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD).
  • The MAD study in AD patients is a planned continuation of the Company’s ongoing single ascending dose (SAD) portion of the Phase 1a/b trial in healthy volunteers.
  • “Dosing the first patient with NM26 represents a major milestone for Numab as we advance development of NM26 in atopic dermatitis and potentially other inflammatory and immune-mediated diseases,” said David Urech, Ph.D., Founder and Chief Executive Officer of Numab Therapeutics.
  • In the United States and the European Union markets, approximately 17-26 million patients suffer from moderate-to-severe AD.

Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease

Retrieved on: 
Wednesday, October 18, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, AD, Orphan Drug Act of 1983, PD, Food, MCI, Rare, DSM-IV codes, HD, European Medicines Agency, Cognitive deficit, Deficit spending, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ODD, Disease, Clinical trial, Marketing, Therapy, NMDA, Patient, Plasma protein binding, Pharmaceutical industry

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718 for the treatment of Huntington’s disease (HD).

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718 for the treatment of Huntington’s disease (HD).
  • Cognitive impairment is one of the most underrecognized aspects of this disease,” said Laura Gault, M.D., Ph.D., Chief Medical Officer, Sage Therapeutics.
  • The approval of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval.
  • SAGE-718 previously received Fast Track Designation from the FDA for HD, and orphan drug designation for HD by the European Medicines Agency.

Chomp's Circular Solution to Food Waste: On-site Anaerobic Digestion

Retrieved on: 
Monday, October 23, 2023
AD, International Energy Agency, Anaerobic digestion, Digestion, Organization, Carbon, Electricity, Multimedia, Methane, Supermarket, Environment, Statistics, Fossil, Soil, GHG, Climate change, Landfill, Sewage treatment, Chomp

To address this pressing concern, On-site Anaerobic Digestion (AD) has emerged as a game-changer in the battle against food waste and its dire environmental consequences.

Key Points: 
  • To address this pressing concern, On-site Anaerobic Digestion (AD) has emerged as a game-changer in the battle against food waste and its dire environmental consequences.
  • Anaerobic digestion, a process that has been used for thousands of years, offers a promising solution to the food waste crisis.
  • Chomp's on-site Anaerobic Digestion distinguishes itself from off-site AD by converting food waste into renewable energy right at the source of generation.
  • To achieve our net-zero emission goals and combat climate change effectively, we must invest in innovative food waste management solutions like on-site Anaerobic Digestion.

Socionext Begins Development of SoCs for Advanced ADAS and AD Using 3nm Automotive Process

Retrieved on: 
Monday, October 23, 2023
Acceleration, TSMC, AD, PPA, EV, ADAS, Life, History, Corporation, Socs, Socionext, Senior, Corporate title, Autonomy, CPU, SOC, Safety, AI, Silicon, Advanced driver-assistance system, Semiconductor, Video game

YOKOHAMA, Japan, Oct. 23, 2023 /PRNewswire/ -- Socionext Inc. today announced it is developing custom SoCs for advanced ADAS (Advanced Driver Assistance Systems) and AD (Autonomous Driving) using N3A, TSMC's latest 3nm automotive process technology.

Key Points: 
  • YOKOHAMA, Japan, Oct. 23, 2023 /PRNewswire/ -- Socionext Inc. today announced it is developing custom SoCs for advanced ADAS (Advanced Driver Assistance Systems) and AD (Autonomous Driving) using N3A, TSMC's latest 3nm automotive process technology.
  • TSMC's 3nm technology enables high-volume production with significant improvements in power, performance, and area (PPA) when compared to previous technology nodes.
  • The SoCs being developed are designed specifically for advanced driving assistance systems and autonomous driving applications, achieving exceptional performance and low power consumption.
  • Through early and close collaboration with TSMC, Socionext aims to be one of the first suppliers of high-performance and energy-efficient automotive products built on the most advanced N3A technology.

Acrylic Coatings Drive Growth in the Organic Coatings Market with Durability and Cost-Effective Benefits

Retrieved on: 
Friday, October 20, 2023
Metal, AD, Eco-friendly dentistry, Construction, Sherwin-Williams, Moisture, BASF, BASF SE, SE, Corrosion, AkzoNobel, Climate change, Adhesive, Paint, Growth

Organic coatings offer long-lasting protection against corrosion, enhance surface stability, and contribute to the durability of metal surfaces.

Key Points: 
  • Organic coatings offer long-lasting protection against corrosion, enhance surface stability, and contribute to the durability of metal surfaces.
  • Acrylic Coatings on the Rise:
    Acrylic coatings, a significant class of organic coatings, are expected to experience substantial growth in the market.
  • The increasing use of acrylic coatings in architectural, industrial, and protective applications is driving their demand, creating lucrative opportunities for the organic coatings market.
  • These companies are at the forefront of innovation and are contributing significantly to the organic coatings market's growth.

TIER IV certified in Level 4 autonomous driving: Sharing its design and process with partners

Retrieved on: 
Friday, October 20, 2023
Tokyo, AD, Certification, Pedestrian, Research, TIER, Environment, IVI, Road, GLP, Road Traffic Act 1934, EVS, Level 4, Perception, Transport, Medical device

Roads within the GLP ALFALINK Sagamihara are regulated by the Road Traffic Act, and used by pedestrians and vehicles.

Key Points: 
  • Roads within the GLP ALFALINK Sagamihara are regulated by the Road Traffic Act, and used by pedestrians and vehicles.
  • Following the guidelines for customizing Level 4 commercial autonomous vehicles published in June 2023 , TIER IV commits to sharing the process and design for this certification as a solution for its partners that aim to develop AD systems, contributing significantly to the realization of autonomous driving.
  • Through continued research and development as well as evaluation and verification, TIER IV aims to further advance functions and performance of AD systems.
  • Building upon the Level 4 certification obtained under the Road Transport Vehicle Act, TIER IV is poised to utilize its knowledge for the mass production and development of electric vehicles (EVs).

HAVAS BOOSTS LEADERSHIP FIREPOWER OF FLAGSHIP NEW YORK AGENCY

Retrieved on: 
Thursday, October 19, 2023
The One Show, Medeiros, One Show, AD, Cannes Lions International Festival of Creativity, Innovation, Lucey, CCO, Collinson, WARC, Creativity, Friends, Drum, Campaign (magazine), Growth, Culture, Vivendi, D, News, Industrial design, Film industry

Sarah Collinson, previously Managing Director of JOAN Creative, has been named CEO of Havas New York and Havas New York's CCO, Dan Lucey, adds Co-CEO to his remit.

Key Points: 
  • Sarah Collinson, previously Managing Director of JOAN Creative, has been named CEO of Havas New York and Havas New York's CCO, Dan Lucey, adds Co-CEO to his remit.
  • "Creativity is at the forefront of our offerings, and we rely on the strength of our people to push that firepower," said Donna Murphy, Global CEO, Havas Creative Network and Havas Health & You.
  • This move reunites Collinson and Lucey, former partners and close friends, and reflects Havas' commitment to furthering its creative chops in North America.
  • In addition to the new leadership structure, Havas New York will further its creative strength by bringing Joao Medeiros from Havas Middle East to New York.